Development of Anti-Ebola MHC Tetramers to Evaluate Vaccines
$250,000Y01FY2010AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Abstract
This IAA supports the development of anti-Ebola MHC tetramers as a surrogate marker to evaluate cell mediated immunity in vaccines.
View original record on NIH RePORTER →